New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
09:16 EDTSGMOSangamo price target raised to $27 from $22 at JMP Securities
JMP Securities increased its price target on Sangamo after meeting with the company's clinical and scientific team. The firm increased its estimate of the likelihood of the company's HIV program succeeding to 60% from 50%. JMP Securities thinks the company is clicking on all cylinders, and reiterates an Outperform rating on the shares.
News For SGMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
07:34 EDTSGMOAlliance for Regenerative Medicine to hold a meeting
Stem Cell Meeting on the Mesa is being held in La Jolla, California on October 7-9.
October 5, 2015
10:19 EDTSGMOSpark trial success a positive for gene therapy sector, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said he views the news that Spark Therapeutics (ONCE) "highly anticipated" SPK-RPE65 Phase 3 gene therapy study for congenital blindness met its primary endpoint as a positive for the ophthalmology gene therapy field as well as the broader gene therapy sector. Schimmer added that Applied Genetic Technologies' (AGTC) early clinical data in the second half of this year will be a further test of the ophthalmology gene therapy platform. The analyst noted that other companies with gene therapy programs include Avalanche (AAVL), Biogen (BIIB), bluebird bio (BLUE), BioMarin (BMRN), Cellectis (CLLS), Medgenics (MDGN), uniQure (QURE), Pfizer (PFE), Regeneron (REGN) and Sangamo (SGMO).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use